Andreas Kungl

Karl-Franzens-University Graz, Institute of Pharmaceutical Sciences, Graz, Austria

INPEC node since 2002

Our research group is mainly interested in studying the interaction of complex (proteo)glycans with proteins such as chemokines, and to turn resulting insights into novel therapies. Our current indication area is immune-oncology with a focus on metastatic lung cancer.

Keywords: protein engineering, proteomics, biophysics, glycobiology, fluorescence spectroscopy, extracellular matrix, drug development